logo-loader
viewWellesley Pharmaceuticals LLC

Wellesley Pharmaceuticals looks to raise $10 million for next round of clinical trials

Wellesley Pharmaceuticals CEO David Dill tells Proactive Investors the privately held company is aiming to treat the frequent need to urinate at night with its drug Nocturol. 

Dill says after the company received "compelling" data from its Phase 2 trials, it's hopeful to sign a licensing agreement with a big pharma to take over its drug. In the meantime, the company is raising capital to fund its next round of trials.

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO highlights 'very strong assay and platform development progress'

VolitionRx Limited's (NYSEAMERICAN:VNRX) president and CEO Cameron Reynolds recaps on what he describes as a year of 'very strong progress' in assay and platform development with its Nu.Q Capture program and epigenetic toolkit Nu.Q Vet. Heading into 2020, Reynolds says the company's well...

2 days, 18 hours ago

2 min read